Thiogenesis Therapeutics Corp (TTIPF)

$0.38 +0.01 (3.51%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 1,500
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada.

Industry: Biotechnology
Sector: Healthcare
Phone: 888-223-9165
Address:
4 King Street West, Suite 401, Toronto, Canada
newsfile_corp
newsfile_corp Feb. 2 at 2:01 PM
https://nfne.ws/282105 $TTIPF $TTI.TSXV #InvestmentBanking #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing
0 · Reply
wavess
wavess Jan. 23 at 10:58 PM
$TTIPF Posted on behalf of Thiogenesis Therapeutics Corp. – Today, Thiogenesis Therapeutics announced interim data from its Phase 2 (EU) clinical study of TTI-0102 in MELAS patients at Mitocon 2026 in Pisa, Italy: https://www.newsfilecorp.com/release/281290/Thiogenesis-Presents-Phase-2-EU-MELAS-Data-at-Mitocon-2026 Notably, the data was selected for the Late-Breaking News session, highlighting high scientific and clinical relevance, and confirmed that "TTI-0102 achieves meaningful biological and clinical proof-of-concept in MELAS when administered using appropriate weight-based dosing"
0 · Reply
newsfile_corp
newsfile_corp Jan. 23 at 2:01 PM
https://nfne.ws/281290 $TTIPF $TTI.TSXV #InvestmentBanking #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing
0 · Reply
wavess
wavess Jan. 15 at 10:47 PM
$TTIPF Posted on behalf of Thiogenesis Therapeutics Corp. – Momentum is building for Thiogenesis Therapeutics as its Phase 2 MELAS program advances, with preliminary pharmacokinetic and pharmacodynamic data for lead candidate TTI-0102 accepted as Late-Breaking News at Mitocon 2026, supporting continued development and potential expansion into additional mitochondrial disorders: https://x.com/StckMasterFlash/status/2011198525992788015
0 · Reply
wavess
wavess Jan. 13 at 9:40 PM
$TTIPF Posted on behalf of Thiogenesis Therapeutics Corp. – Today, Thiogenesis Therapeutics announced that an abstract outlining preliminary pharmacokinetic and pharmacodynamic results from its Phase 2 clinical trial of TTI-0102 in MELAS has been accepted as Late-Breaking News at the Mitocon Conference 2026, taking place January 23–26 in Pisa, Italy: https://www.newsfilecorp.com/release/280089/Thiogenesis-Therapeutics-MELAS-Abstract-Accepted-for-LateBreaking-News-Presentation-at-Mitocon-2026 The Phase 2 study is a randomized, double-blind, placebo-controlled, multi-center trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of oral TTI-0102 in patients with MELAS. Previously reported interim results demonstrated biological proof-of-concept and biomarker activity supporting the drug’s proposed mechanism of action.
0 · Reply
newsfile_corp
newsfile_corp Jan. 13 at 2:01 PM
https://nfne.ws/280089 $TTIPF $TTI.TSXV #InvestmentBanking #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing
0 · Reply
wavess
wavess Jan. 7 at 11:11 PM
$TTIPF Posted on Behalf of Thiogenesis Therapeutics Corp. – Thiogenesis Therapeutics is advancing a focused clinical strategy targeting severe mitochondrial diseases with no approved therapies, while increasing its visibility within the mitochondrial disease community: https://www.newsfilecorp.com/release/279392/Thiogenesis-to-Present-Clinical-Updates-in-MELAS-and-Leigh-Syndrome-Spectrum-at-UMDF-BenchtoBedside-Webinar With a completed Phase 2 study in MELAS, a U.S. Phase 2a trial approaching in Leigh syndrome spectrum, and a differentiated prodrug designed to improve dosing and tolerability, TTI is steadily building clinical momentum in a space defined by high unmet need and limited therapeutic options.
0 · Reply
SkywalkerofLuke
SkywalkerofLuke Jan. 6 at 10:09 PM
$TTIPF Posted on behalf of Thiogenesis Therapeutics Corp. - Last month Thiogenesis Therapeutics Corp. (TTI.v TTIPF) announced plans to initiate a Phase 3 pivotal clinical trial of its lead compound TTI-0102 for the treatment of nephropathic cystinosis, an inherited lysosomal storage disorder requiring lifelong cystine-depleting therapy. CEO of Thiogenesis, Dr. Patrice Rioux, commented, “TTI-0102 was engineered specifically to overcome the limitations of existing cysteamine formulations. By enabling the potential for once-daily or reduced dosing with a far better tolerability profile, we believe TTI-0102 represents the next-generation therapy that patients and families that would significantly increase their quality of life.” https://cdn.prod.website-files.com/6324f3c1cd40a857e0ea27a4/6926338767b7d1dfbc68b977_TTI%20NR%20251124%20Cystinosis%20Ph%203%20(F).pdf
0 · Reply
newsfile_corp
newsfile_corp Jan. 5 at 2:00 PM
https://nfne.ws/279392 $TTIPF $TTI.TSXV #InvestmentBanking #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing
0 · Reply
wavess
wavess Dec. 12 at 10:43 PM
$TTIPF Posted on Behalf of Thiogenesis Therapeutics Corp. – Following positive interim Phase 2 MELAS data and a clear regulatory path in nephropathic cystinosis, Thiogenesis Therapeutics is advancing toward pivotal Phase 3 trials with TTI-0102, its next-generation sulfur-based prodrug designed to improve tolerability and simplify dosing for severe pediatric mitochondrial and metabolic diseases: https://www.reddit.com/r/PennyStocksCanada/comments/1pf9k7f/thiogenesis_therapeutics_outlines_phase_3_plans/
0 · Reply
Latest News on TTIPF
No data available.
newsfile_corp
newsfile_corp Feb. 2 at 2:01 PM
https://nfne.ws/282105 $TTIPF $TTI.TSXV #InvestmentBanking #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing
0 · Reply
wavess
wavess Jan. 23 at 10:58 PM
$TTIPF Posted on behalf of Thiogenesis Therapeutics Corp. – Today, Thiogenesis Therapeutics announced interim data from its Phase 2 (EU) clinical study of TTI-0102 in MELAS patients at Mitocon 2026 in Pisa, Italy: https://www.newsfilecorp.com/release/281290/Thiogenesis-Presents-Phase-2-EU-MELAS-Data-at-Mitocon-2026 Notably, the data was selected for the Late-Breaking News session, highlighting high scientific and clinical relevance, and confirmed that "TTI-0102 achieves meaningful biological and clinical proof-of-concept in MELAS when administered using appropriate weight-based dosing"
0 · Reply
newsfile_corp
newsfile_corp Jan. 23 at 2:01 PM
https://nfne.ws/281290 $TTIPF $TTI.TSXV #InvestmentBanking #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing
0 · Reply
wavess
wavess Jan. 15 at 10:47 PM
$TTIPF Posted on behalf of Thiogenesis Therapeutics Corp. – Momentum is building for Thiogenesis Therapeutics as its Phase 2 MELAS program advances, with preliminary pharmacokinetic and pharmacodynamic data for lead candidate TTI-0102 accepted as Late-Breaking News at Mitocon 2026, supporting continued development and potential expansion into additional mitochondrial disorders: https://x.com/StckMasterFlash/status/2011198525992788015
0 · Reply
wavess
wavess Jan. 13 at 9:40 PM
$TTIPF Posted on behalf of Thiogenesis Therapeutics Corp. – Today, Thiogenesis Therapeutics announced that an abstract outlining preliminary pharmacokinetic and pharmacodynamic results from its Phase 2 clinical trial of TTI-0102 in MELAS has been accepted as Late-Breaking News at the Mitocon Conference 2026, taking place January 23–26 in Pisa, Italy: https://www.newsfilecorp.com/release/280089/Thiogenesis-Therapeutics-MELAS-Abstract-Accepted-for-LateBreaking-News-Presentation-at-Mitocon-2026 The Phase 2 study is a randomized, double-blind, placebo-controlled, multi-center trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of oral TTI-0102 in patients with MELAS. Previously reported interim results demonstrated biological proof-of-concept and biomarker activity supporting the drug’s proposed mechanism of action.
0 · Reply
newsfile_corp
newsfile_corp Jan. 13 at 2:01 PM
https://nfne.ws/280089 $TTIPF $TTI.TSXV #InvestmentBanking #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing
0 · Reply
wavess
wavess Jan. 7 at 11:11 PM
$TTIPF Posted on Behalf of Thiogenesis Therapeutics Corp. – Thiogenesis Therapeutics is advancing a focused clinical strategy targeting severe mitochondrial diseases with no approved therapies, while increasing its visibility within the mitochondrial disease community: https://www.newsfilecorp.com/release/279392/Thiogenesis-to-Present-Clinical-Updates-in-MELAS-and-Leigh-Syndrome-Spectrum-at-UMDF-BenchtoBedside-Webinar With a completed Phase 2 study in MELAS, a U.S. Phase 2a trial approaching in Leigh syndrome spectrum, and a differentiated prodrug designed to improve dosing and tolerability, TTI is steadily building clinical momentum in a space defined by high unmet need and limited therapeutic options.
0 · Reply
SkywalkerofLuke
SkywalkerofLuke Jan. 6 at 10:09 PM
$TTIPF Posted on behalf of Thiogenesis Therapeutics Corp. - Last month Thiogenesis Therapeutics Corp. (TTI.v TTIPF) announced plans to initiate a Phase 3 pivotal clinical trial of its lead compound TTI-0102 for the treatment of nephropathic cystinosis, an inherited lysosomal storage disorder requiring lifelong cystine-depleting therapy. CEO of Thiogenesis, Dr. Patrice Rioux, commented, “TTI-0102 was engineered specifically to overcome the limitations of existing cysteamine formulations. By enabling the potential for once-daily or reduced dosing with a far better tolerability profile, we believe TTI-0102 represents the next-generation therapy that patients and families that would significantly increase their quality of life.” https://cdn.prod.website-files.com/6324f3c1cd40a857e0ea27a4/6926338767b7d1dfbc68b977_TTI%20NR%20251124%20Cystinosis%20Ph%203%20(F).pdf
0 · Reply
newsfile_corp
newsfile_corp Jan. 5 at 2:00 PM
https://nfne.ws/279392 $TTIPF $TTI.TSXV #InvestmentBanking #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing
0 · Reply
wavess
wavess Dec. 12 at 10:43 PM
$TTIPF Posted on Behalf of Thiogenesis Therapeutics Corp. – Following positive interim Phase 2 MELAS data and a clear regulatory path in nephropathic cystinosis, Thiogenesis Therapeutics is advancing toward pivotal Phase 3 trials with TTI-0102, its next-generation sulfur-based prodrug designed to improve tolerability and simplify dosing for severe pediatric mitochondrial and metabolic diseases: https://www.reddit.com/r/PennyStocksCanada/comments/1pf9k7f/thiogenesis_therapeutics_outlines_phase_3_plans/
0 · Reply
wavess
wavess Dec. 9 at 11:48 PM
$TTIPF Posted on Behalf of Thiogenesis Therapeutics Corp. – Marking a major step forward in rare-disease therapeutics, Thiogenesis Therapeutics recently announced plans to launch a pivotal Phase 3 trial in 2026 for TTI-0102, a next-generation cysteamine prodrug designed to transform treatment for nephropathic cystinosis, a $300M global market with urgent unmet need: https://x.com/StckMasterFlash/status/1993031569196413073 For more information on TTI and its pipeline which additionally includes clinical trials for MELAS, LSS and pediatric MASH, register to attend their presentation at the Life Sciences Virtual Investor Forum on December 11th, 2025: https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/146150/december-11th-life-sciences-virtual-investor-forum
0 · Reply
stockhawk12
stockhawk12 Dec. 4 at 11:42 PM
Posted on behalf of Thiogenesis Therapeutics, Corp. - Thiogenesis $TTI.V $TTIPF is developing sulfur-based prodrugs to address serious mitochondrial and metabolic disorders. With positive interim Phase 2 MELAS trial results now in hand and plans to initiate a Phase 3 clinical nephropathic cystinosis trial, TTI is entering a pivotal stage as it prepares for several major clinical milestones across its rare-disease pipeline. More here: https://www.thiogenesis.com/investors
0 · Reply
wavess
wavess Dec. 3 at 8:59 PM
$TTIPF Posted on Behalf of Thiogenesis Therapeutics Corp. – Continuing to expand its clinical footprint, Thiogenesis Therapeutics is strengthening its broader development pipeline in advancing toward a 2026 Phase 3 pivotal trial for nephropathic cystinosis: https://x.com/StckMasterFlash/status/1993031569196413073 This comes alongside its Phase 2 clinical trial of TTI-0102 for MELAS which recently returned positive interim results, as well as additional trials in pediatric MASH and LSS.
0 · Reply
wavess
wavess Dec. 2 at 11:44 PM
$TTIPF Posted on Behalf of Thiogenesis Therapeutics Corp. – Moving toward a major clinical milestone, Thiogenesis Therapeutics announced plans to file an IND in early 2026 and launch a Phase 3 pivotal trial for TTI-0102, a next-generation, once-daily cysteamine prodrug designed to solve long-standing tolerability and dosing challenges in nephropathic cystinosis, a rare disease market exceeding $300 million: https://x.com/StckMasterFlash/status/1993031569196413073
0 · Reply
wavess
wavess Nov. 28 at 5:40 PM
$TTIPF Posted on behalf of Thiogenesis Therapeutics Corp. – In 2026, Thiogenesis Therapeutics intends to launch a Phase 3 pivotal trial for TTI-0102 to improve dosing convenience and tolerability for patients with nephropathic cystinosis, a rare lysosomal disorder with a global market exceeding $300 million: https://x.com/StckMasterFlash/status/1993031569196413073 TTI expects to file its IND in early 2026, advancing a once-daily, potentially better-tolerated alternative to current cysteamine therapies.
0 · Reply
stockhawk12
stockhawk12 Nov. 27 at 12:10 AM
Posted on behalf of Thiogenesis Therapeutics, Corp. - Thiogenesis Therapeutics $TTI.V $TTIPF is planning a Phase 3 trial of its lead drug for nephropathic cystinosis, a rare recessive disorder which results in progressive multi-organ damage. TTI is pursuing a streamlined regulatory pathway & aims to file an Investigational New Drug application in early 2026. More here⬇️ https://www.reddit.com/r/PennyStocksCanada/comments/1p6xyc6/thiogenesis_therapeutics_ttiv_ttipf_outlines/
0 · Reply
wavess
wavess Nov. 24 at 6:43 PM
$TTIPF Posted on Behalf of Thiogenesis Therapeutics Corp. - Today, Thiogenesis Therapeutics announced plans to initiate a Phase 3 pivotal clinical trial in 2026 for its lead drug candidate TTI-0102, targeting nephropathic cystinosis, a rare lysosomal storage disorder: https://www.newsfilecorp.com/release/275563/Thiogenesis-Therapeutics-Expands-on-Plans-for-Phase-3-Pivotal-Trial-of-TTI0102-in-Nephropathic-Cystinosis With an investigational New Drug application is planned for early 2026, the trial is targeting a global patient population exceeds 2,000, representing a market of over $300 million.
0 · Reply
newsfile_corp
newsfile_corp Nov. 24 at 2:00 PM
https://nfne.ws/275563 $TTIPF $TTI.TSXV #InvestmentBanking #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing
0 · Reply
stockhawk12
stockhawk12 Nov. 21 at 11:43 PM
Posted on behalf of Thiogenesis Therapeutics Corp. – Thiogenesis Therapeutics $TTI.V $TTIPF reported early Phase 2 data for its lead drug in MELAS, supporting its biological activity & showing biomarker improvements. Dosing issues in lighter patients will guide future trials as TTI advances programs in Leigh syndrome & nephropathic cystinosis. More⬇️ https://www.reddit.com/r/CanadaStocks/comments/1owfe79/thiogenesis_therapeutics_ttiv_ttipf_reports_early/
0 · Reply
wavess
wavess Nov. 19 at 6:52 PM
$TTIPF Posted on Behalf of Thiogenesis Therapeutics Corp. - Thiogenesis Therapeutics released positive interim data from its Phase 2 MELAS trial, showing that once-daily TTI-0102 was well tolerated in patients over 70 kg and delivered biomarker improvements consistent with its mitochondrial-restorative mechanism: https://x.com/StckMasterFlash/status/1985823585139876182 With these results meeting proof-of-concept thresholds and informing dosing ahead of a planned Phase 3 study in 2026, TTI is moving into a pivotal stretch across its MELAS, Leigh syndrome, and cystinosis programs.
0 · Reply
BigShmoneyHoney
BigShmoneyHoney Nov. 18 at 11:32 PM
$TTIPF Posted on behalf of Thiogenesis Therapeutics, Corp: Thiogenesis Therapeutics reported encouraging interim Phase 2 results for its lead compound TTI-0102 in MELAS, confirming strong safety, biomarker response, and proof-of-concept for its mitochondrial-restorative mechanism. Phase 2 Highlights (MELAS) • Well-tolerated in larger patients (>70 kg), consistent with Phase 1 safety data. • Clear biomarker differentiation supports efficacy signal. • Refined dosing underway to improve tolerance in lighter patients. • Final 6-month data expected January 2026; pivotal Phase 3 trial to begin in Europe next year. Pipeline Expansion • Leigh Syndrome Spectrum – IND accepted by FDA; Phase 2 trial starts early 2026 at a major U.S. children’s hospital. • Nephropathic Cystinosis – Phase 3 non-inferiority trial planned vs. cysteamine; aims for once-daily dosing and reduced GI side effects. https://www.reddit.com/r/Inflation_Investment/comments/1p0r2p1/thiogenesis_therapeutics_ttiv_ttipf_positive/
0 · Reply
stockhawk12
stockhawk12 Nov. 11 at 11:36 PM
$TTIPF $TTI.V recently shared positive interim Phase 2 drug trial results for MELAS, achieving biological proof-of-concept, dose discovery & biomarker improvement. The results support progressing to Phase 3 for MELAS and TTI's Leigh Syndrome & Nephropathic Cystinosis programs. More⬇️ https://www.reddit.com/r/CanadaStocks/comments/1oqfq99/thiogenesis_therapeutics_ttiv_ttipf_reports/ *Posted on behalf of Thiogenesis Therapeutics Corp.
0 · Reply